Neuro: Drugs for Movement Disorders Flashcards
In parkinsons, ____ cannot be released from the substantia nigra so these patients cannot put on the brake
Dopmaine
MOA of amantadie
increases dopamine release and prevents reuptake
Weak NMDA receptor antagonist (less glutamate excitement)
What is the clinical application of amantadine?
Mono or adjuctive therapy for PD
Adverse effects of amantadine
CNS depression, Impulse Control Psychosis Suicidal ideation Livedo reticularis and ataxia
MOA of ropinirole
D2 and D3 non-ergot receptor agonist
Adverse effects of ropinirole
Dyskinesias Impulse control Increase risk for melanoma Orthostatics Psychosis Somnolence
MOA of Selegiline and Rasagiline
IRREVESIBLE MAO-B inhibitor, so dopamine doesn’t get converted to DOPAC
Adverse effects of selegiline?
Antidepressants increase risk of suicidal thoughts and behaviors in peds and young adults
What MAO-B inhibitors are reversible?
safinamide
MOA of tolcapone
Peripheral and Central COMT inhibitor
-DA not broken down into 3-MT
When are tolcapone/entacapone used?
adjunctive therapy to Carbidopa/L-DOPA
Toxicity of tolcapone
Hepatoxicity (BB warning) CNS depression Impulse control issues Orthostatics Dyskinesia exacerbation
Does entacapone work in CNS or periphery?
Periphery only
-cannot cross BBB
MOA of carbidopa
inhibits peripheral L-DOPA decarboxylase
-L-DOPA not converted to dopamine
Adverse effects of carbidopa? (6)
GI effects Postural hypotension Cardiac arrythmias Dyskinesias Behavioral effects Wearing off and On-Off phenomena